Sleepy Head Pacifier Max 53% OFF Holder And Baby Gift Book $5 Sleepy Head Pacifier Holder And Gift Book Baby Baby Feeding Pacifier Clips & Cases Head,Baby,$5,/ginglymoidal1275052.html,And,Gift,Book,Pacifier,Baby , Feeding , Pacifier Clips & Cases,Sleepy,Holder,hagitmounitz.com Head,Baby,$5,/ginglymoidal1275052.html,And,Gift,Book,Pacifier,Baby , Feeding , Pacifier Clips & Cases,Sleepy,Holder,hagitmounitz.com Sleepy Head Pacifier Max 53% OFF Holder And Baby Gift Book $5 Sleepy Head Pacifier Holder And Gift Book Baby Baby Feeding Pacifier Clips & Cases

Sleepy Head Pacifier Max 53% OFF Holder And Baby Sales of SALE items from new works Gift Book

Sleepy Head Pacifier Holder And Gift Book Baby

$5

Sleepy Head Pacifier Holder And Gift Book Baby

|||

Item specifics

Condition:
New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is ...
Brand:
Banded
Type:
Pacifier Holder
Theme:
Bear
UPC:
Does not apply









Sleepy Head Pacifier Holder And Gift Book Baby

Intro Pullout Text Widget

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.7
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of Wakeboard Double Up Sam Owens 135.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via T2: France Silver 1808 A 1/2 Franc and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple PodcastFitting 8mm or 5/16" OD Tube Weld to 10mm or 3/8" ID Banjo SteelGoogle PodcastsMedtronic Activity Guard ACC-1520 630G/670G/770G (b)Stitcher and Rare Topaz Jade Sculpture Talisman Fish Netsuke Old Pet No.294

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

Free Lay Summaries

Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?

 

ARD provides free lay summaries for selected research articles and all EULAR recommendations.

 

These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access

 

Each recommendation also has an accompanying lay summary, which is also free to access.

Video Abstract

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE

To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.

Podcasts